<DOC>
	<DOCNO>NCT00016718</DOCNO>
	<brief_summary>Treatment HIV-infected patient involve combine drug different class anti-HIV drug . One preferred regimen adult 2 nucleoside reverse transcriptase inhibitor ( NRTIs ) 1 protease inhibitor ( PI ) . For child , regimen may complicate drug may difficult take mouth . The purpose study determine long-term safety effectiveness daily didanosine ( ddI ) , efavirenz ( EFV ) , emtricitabine ( FTC ) pediatric patient take anti-HIV drug .</brief_summary>
	<brief_title>Safety Effectiveness Emtricitabine , Efavirenz , Didanosine HIV Infected Children Who Have Taken Few No Anti-HIV Drugs</brief_title>
	<detailed_description>Anti-HIV treatment option limit pediatric patient combination therapy recommend adult may appropriate child adolescent . Few PIs available formulation appropriate pediatric patient , complex dosing schedule food requirement may detrimental treatment adherence . A once-daily regimen NRTIs ddI FTC nonnucleoside reverse transcriptase inhibitor ( NNRTI ) EFV show safe well tolerate adult . This study evaluate long-term safety efficacy ddI , FTC , EFV regimen pediatric patient . Patients follow maximum 192 week ; patient receive ddI , EFV , FTC together daily . Study visit occur study entry , Weeks 2 4 , every 4 week thereafter . Blood collection , medical history assessment , physical exam occur visit ; urine collection occur select visit . Intensive pharmacokinetic ( PK ) study do Weeks 2 12 determine dose adjustment require drug . If virologic failure determine , PK study repeat 4 week adjustment therapy . Parents guardian ask complete treatment adherence questionnaires visit . Some patient may also ask participate additional PK study Week 16 week 96 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>HIV infect Antiretroviral naive OR receive 56 day drug prevent mothertochild transmission HIV OR receive less 7 total day antiretroviral therapy Viral load 5,000 copies/ml Parent guardian willing provide inform consent , applicable Willing use acceptable form contraception Allergic study medication formulation Kidney disease Positive hepatitis B C AIDSrelated infection require treatment study entry Taking drug treat tuberculosis Taking antiHIV drug include study Taking investigational drug Anticancer drug within 1 year study screen Serious medical event within 21 day study screen Active history pancreatitis Require certain medication . Patients require short course steroid ( less 14 day ) asthma exclude . Active history significant peripheral neuropathy Difficulty food severe chronic diarrhea within 30 day study entry Unable eat least 1 meal per day ( fee least 3 time per day , infant ) chronic nausea , vomit , swallow problem , stomach upset Unable swallow oral medication Pregnant breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>90 Days</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Drug Administration Schedule</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Deoxycytidine</keyword>
	<keyword>Efavirenz</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>